Clinical trials: PD
Parkinson's Disease
A Dose Finding Study of Preladenant (SCH 420814) for the Treatment of Parkinson's Disease (PD) in Japanese Patients (P06402)
This study is to evaluate the efficacy of a range of preladenant doses compared with placebo in participants with moderate to severe Parkinson's disease (PD) experiencing motor fluctuations and receiving a stable dose of levodopa…
- Trial name
- NCT01294800
- Testing
- Preladenant
- Volunteers
- 450 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Cancer
Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC
Mocetinostat (MGCD0103) is an orally administered HDAC inhibitor. Durvalumab (MEDI4736) is a human monoclonal antibody that is an inhibitor of the Programmed Cell Death Ligand (or PD-L1).
- Trial name
- NCT02805660
- Testing
- Mocetinostat - 50 mg, Mocetinostat - 70 mg, Mocetinostat - 90 mg
- Where
- 15 sites in United States
- Volunteers
- 83 people
- Sponsor
- Mirati Therapeutics Inc.
Breast Cancer
Study of Pembrolizumab (MK-3475) Monotherapy for Metastatic Triple-Negative Breast Cancer (MK-3475-086/KEYNOTE-086)
This is a two-part study of pembrolizumab monotherapy in participants with metastatic triple-negative breast cancer (mTNBC). Part 1 of the study will examine the efficacy and safety of pembrolizumab monotherapy as first line or…
- Trial name
- NCT02447003
- Testing
- Pembrolizumab
- Volunteers
- 254 people
- Sponsor
- Merck Sharp & Dohme LLC
Parkinson's Disease
Impact of Walking Practice on Persons With PD
The purpose of this study is to investigate the impact of a specifically designed leg brace on walking endurance in individuals with Parkinson's disease.
- Trial name
- NCT02113189
- Testing
- Walking program with ankle brace, Individualized walking program, Walking program with custom braces.
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Texas Southwestern Medical Center
Non-Small-Cell Lung Cancer
Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Pembrolizumab (MK-3475) in Chinese Participants With Non-Small-Cell Lung Cancer (MK-3475-032/KEYNOTE-032)
The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and efficacy of three doses of pembrolizumab (MK-3475) in adult Chinese participants with locally advanced or metastatic non-small-cell lung…
- Trial name
- NCT02835690
- Testing
- Pembrolizumab
- Volunteers
- 44 people
- Sponsor
- Merck Sharp & Dohme LLC
Early Parkinson Disease (Early PD)
Efficacy, Safety, Tolerability of Pramipexol ER Versus Pramipexol IR Versus Placebo in Early PD Patients
The objectives of this trial conducted in early Parkinson's Disease (PD) patients are to determine the efficacy (as measured by the change from baseline to the end of the maintenance phase in the total score for the Unified…
- Trial name
- NCT00479401
- Testing
- Pramipexol Extended Release, Pramipexol Immediate Release
- Where
- 95 sites in United States, Argentina and 12 more
- Volunteers
- 539 people
- Sponsor
- Boehringer Ingelheim
Squamous Cell Carcinoma of Head and Neck, Non-small Cell Lung Cancer
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
A Phase 1/2, open label, multi-center study to evaluate the safety, efficacy and tolerability of alomfilimab as single agent and in combination with anti-PD-L1 (atezolizumab) in adult patients with selected advanced malignancies…
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Esophageal Cancer
- Trial name
- NCT03829501
- Testing
- Alomfilimab, Atezolizumab
- Where
- 22 sites in United States, Hungary and 4 more
- Volunteers
- 222 people
- Sponsor
- Kymab Limited
Endometriosis
A Study of Pharmacokinetic/Pharmacodynamic Profile of Orally Administered Leuprolide in Healthy Female Volunteers
This Phase 2a, pharmacokinetic/pharmacodynamic study will determine the safety and provide evaluation of the PK/PD metrics of three different oral doses selected upon the results of the study LOPDT-PH1-01 - 4 mg oral tablets…
- Trial name
- NCT02807363
- Testing
- Leuprolide Oral Tablet 4-mg QD, Leuprolide Oral Tablet 4-mg BID, Leuprolide Depot
- Where
- Canada
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Enteris BioPharma Inc.
Melanoma
Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006)
This study will evaluate the safety and efficacy of 2 different dosing schedules of pembrolizumab (MK-3475), every 2 weeks (Q2W) and every 3 weeks (Q3W), and compare the 2 schedules to treatment with ipilimumab in…
- Trial name
- NCT01866319
- Testing
- Pembrolizumab, Ipilimumab
- Volunteers
- 834 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer
Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007)
The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combined with lenvatinib (MK-7902/E7080) compared to pembrolizumab alone (with placebo for lenvatinib) in treatment-naïve adults with no…
- Trial name
- NCT03829332
- Testing
- Pembrolizumab, Lenvatinib
- Where
- 162 sites in United States, Australia and 17 more
- Volunteers
- 623 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer, Carcinoma
Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer
This was a Phase 1/2, open-label, multicenter, single-arm study of combination therapy with ensartinib, an anaplastic lymphoma kinase (ALK) inhibitor, and durvalumab, an anti-programmed cell death ligand 1 (PD-L1) antibody, in…
- Conditions
- Non-small Cell Lung Cancer, Carcinoma, NSCLC
- Trial name
- NCT02898116
- Testing
- Ensartinib, Durvalumab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Ludwig Institute for Cancer Research
Metastatic Breast Cancer
Anti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2-positive Breast Cancer
Panacea is a phase Ib/II trial evaluating the efficacy of MK-3475 and trastuzumab in patients with trastuzumab-resistant, HER2- positive metastatic breast cancers
- Trial name
- PANACEA (NCT02129556)
- Testing
- MK-3475
- Where
- 11 sites in Australia, Austria and 3 more
- Volunteers
- 58 people
- Sponsor
- ETOP IBCSG Partners Foundation
Parkinson Disease
A Study That Compares the Extent to Which Apomorphine Becomes Available in the Body After Taking Either an Investigational Drug Containing Apomorphine or Apomorphine That is Injected Under the Skin in People With PD Complicated by "OFF" Episodes
A study that compares the extent to which apomorphine becomes available in the body after taking either an investigational drug containing apomorphine or apomorphine that is injected under the skin in people with PD complicated…
- Trial name
- NCT03292016
- Testing
- APL-130277, APO-go, Apokyn
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- Sumitomo Pharma America, Inc.
Type 1 Diabetes Mellitus
BMS - Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin in Type 1 Diabetes
To obtain safety and tolerability information in patients with type 1 diabetes where Dapagliflozin is added on to Insulin (for 14 days)
- Trial name
- NCT01498185
- Testing
- Dapagliflozin
- Where
- 12 sites in United States
- Volunteers
- 171 people
- Sponsor
- AstraZeneca
Germ Cell Neoplasms, Testicular Neoplasms
Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors
This is an open label, multi-institutional, single arm phase II trial of pembrolizumab in patients with incurable platinum refractory germ cell tumors. No randomization or blinding is involved.
- Conditions
- Germ Cell Neoplasms, Testicular Neoplasms, Non Seminomatous Germ Cell Tumors, Mediastinal Neoplasms
- Trial name
- NCT02499952
- Testing
- Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Nasser Hanna, M.D.
Ovarian Cancer, Fallopian Tube Cancer
Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)
The purpose of this study is to assess the efficacy and safety of treatment with carboplatin/paclitaxel* PLUS pembrolizumab (MK-3475) and maintenance olaparib (MK-7339) in women with epithelial ovarian cancer (EOC), fallopian…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms
- Trial name
- NCT03740165
- Testing
- Pembrolizumab, Carboplatin, Paclitaxel
- Where
- 227 sites in United States, Australia and 20 more
- Volunteers
- 1,367 people
- Sponsor
- Merck Sharp & Dohme LLC
Metastatic Cancer, Solid Tumors
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
This study is an open-label Phase 1/Phase 2 evaluation of INCB001158 as a single agent and in combination with immune checkpoint therapy in patients with advanced/metastatic solid tumors.
- Conditions
- Metastatic Cancer, Solid Tumors, Colorectal Cancer (CRC), Gastric Cancer
- Trial name
- NCT02903914
- Testing
- INCB001158, Pembrolizumab
- Where
- 20 sites in United States, Italy and 2 more
- Volunteers
- 260 people
- Sponsor
- Incyte Corporation
Clear Cell Renal Cell Carcinoma
Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma
The study will evaluate the clinical activity of sitravatinib in combination with nivolumab in patients with locally-advanced clear cell renal cell carcinoma (ccRCC) in the neoadjuvant setting prior to nephrectomy.
- Trial name
- NCT03680521
- Testing
- Sitravatinib, Nivolumab
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Mirati Therapeutics Inc.
Colonic Neoplasms
PK/PD Investigation of Modufolin (Arfolitixorin) in Plasma, Tumor and Adjacent Mucosa Adjacent Mucosa in Patients With Colon Cancer
The purpose of this study is to compare the concentration of four different metabolites in the tumor, in adjacent mucosa and in plasma in patients with colon cancer receiving two different doses of Modufolin (arfolitixorin) and…
- Trial name
- NCT01681472
- Testing
- 6R-MTHF (arfolitixorin) 200 mg/m2, Levoleucovorin 200 mg/m2, 6R-MTHF (arfolitixorin) 60 mg/m2
- Where
- Sweden
- Volunteers
- 32 people
- Sponsor
- Isofol Medical AB
Parkinson's Disease
Highly Challenging Balance Program to Reduce Fall Rate in PD
This study will test the hypothesis that two highly challenging exercise programs, one based at the VA medical center and the other conducted remotely, will both significantly reduce overall fall rates in patients with…
- Trial name
- NCT03972969
- Testing
- Facility-based structured exercise, Home-based structured exercise, Health education
- Where
- United States
- Volunteers
- 162 people
- Sponsor
- VA Office of Research and Development